Comprehensive analysis of Major depression Related gene Signature for predicting prognosis in lung adenocarcinoma

Abstract

Abstract Background Lung adenocarcinoma (LUAD) is one of the most common types of cancer in the world, which has attracted much attention due to its high heterogeneity, invasiveness and metastasis. In recent years, depression has been proved to be related to the occurrence and development of various tumors. However, the regulatory pathway of depression related genes on tumor immune microenvironment and how the underlying mechanisms affect the prognosis of LUAD patients remain unclear. Methods In this study, we obtained common differentially expressed genes of LUAD patients and MDD patients through R software package "Limma". The relationship between Co-dysregulated genes and metabolism was investigated by KEGG enrichment analysis. According to survival analysis, we screened and constructed Diffgene | Neuropeptides related to prognosis. Finally, the prediction model is constructed using the LASSO algorithm and Cox regression, and its prediction ability is verified. Results This study constructed a risk assessment model for LUAD patients based on the 9 neuropeptide genes most related to the prognosis of lung adenocarcinoma, and showed significant predictive effect. The enrichment analysis results of MDD and LUAD Co-dysregulated genes obtained show that the up-regulated genes are enriched in Axon guidance, Ras signaling path, MAPK signaling path, and the down-regulated genes are significantly enriched in Jak-STAT signaling path, Fc epsilon RI signaling path. The results of single cell sequencing data analysis showed that in the high-risk population, it was significantly enriched with ethoxylates, dicarboxylic acid metabolism and pentose phosphate pathway. The low-risk group was more inclined to glycosaminoglycan synthesis, heparin sulfate metabolism and vitamin B6 metabolism. Conclusions In general, our study proves for the first time that MDD related gene play an important role in the prognosis of LUAD. The personalized evaluation based on Diffgene | neuropeptide scoring model can accurately predict the prognosis of LUAD patients.